Detalhe da pesquisa
1.
Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
Lupus
; 31(8): 974-984, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35593174
2.
Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose
Clinics
; 78: 100150, 2023. tab, graf
Artigo
em Inglês
|
LILACS-Express
| ID: biblio-1421262